MGLL and Parkinson disease: Data collected by Nomura et al. in 2011 demonstrated that both genetic (Mgll −/− mice) and pharmacological (pretreatment with JZL184, 40 mg/kg, v.o.)inactivation of MAGL in an acute MPTP-induced parkinsonism model (15 mg/kg, i.p.)led to reducing levels of AA, prostaglandins, and proinflammatory cytokines.